Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

109.07
Delayed Data
As of Aug 28
 +4.17 / +3.98%
Today’s Change
63.48
Today|||52-Week Range
140.00
+12.44%
Year-to-Date
No recent news for Alnylam Pharmaceuticals Inc.

Today’s Trading

Previous close104.90
Today’s open104.59
Day’s range104.59 - 109.72
Volume723,192
Average volume (3 months)742,906
Market cap$9.2B
Dividend yield--
Data as of 3:59pm ET, 08/28/2015

Growth & Valuation

Earnings growth (last year)-234.48%
Earnings growth (this year)+32.53%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+7.20%
P/E ratioNM
Price/Sales142.50
Price/Book8.99

Competitors

 Today’s
change
Today’s
% change
QQuintiles Transnatio...+1.04+1.40%
ISISIsis Pharmaceuticals...-0.02-0.04%
ICLRICON PLC-0.76-0.97%
PRXLPAREXEL Internationa...-1.73-2.50%
Data as of 4:03pm ET, 08/28/2015

Financials

Next reporting dateNovember 4, 2015
EPS forecast (this quarter)-$0.90
Annual revenue (last year)$50.6M
Annual profit (last year)-$360.4M
Net profit margin-712.79%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President &
Chief Operating Officer
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts

Partner Offers